Skip to main content

Eluxadoline Disease Interactions

There are 3 disease interactions with eluxadoline.

Major

Eluxadoline (applies to eluxadoline) constipation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of eluxadoline is contraindicated in patients with history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. These patients may be at risk for severe complications of bowel obstruction.

References

  1. (2015) "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.
Major

Eluxadoline (applies to eluxadoline) pancreatitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Biliary Obstruction, Gallbladder Disease, Alcoholism

Pancreatitis, with or without sphincter of Oddi spasm has been reported in patients taking either the 75 mg or 100 mg dosage of eluxadoline, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported. The use of eluxadoline is contraindicated in patients without a gallbladder and in other patients at risk of pancreatitis such as patients with alcoholism, patients with known or suspected bile duct obstruction, history of pancreatitis or structural disease of the pancreas. In patients with a gallbladder, the alcohol intake of the patient should be evaluated before starting treatment. Patients should be monitored for any signs or symptoms suggestive of pancreatitis. Patients should be instructed to stop treatment immediately and seek medical attention.

References

  1. (2015) "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.
Major

Eluxadoline (applies to eluxadoline) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Eluxadoline is contraindicated in patients with severe hepatic impairment, as these patients are at risk for significantly increased plasma concentrations (16- fold), and there is no information to support the safety on these patients. In patients with mild to moderate hepatic impairment the plasma concentrations are increased to a lesser extent. It is recommended to decrease the dose to 75 mg twice a day on these patients and monitor regularly for impaired mental or physical abilities and for any other eluxadoline related adverse reactions.

References

  1. (2015) "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.

Eluxadoline drug interactions

There are 211 drug interactions with eluxadoline.

Eluxadoline alcohol/food interactions

There is 1 alcohol/food interaction with eluxadoline.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer